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Objective: Mutated p53 gene is related to the instability of cell growth and cell cycle progression. We aimed to 
evaluate the association between endometriosis and p53 codon 11, 72 and 248 gene polymorphisms. 
Patients and methods: Women were divided into two groups: (1) moderate/severe endometriosis (n=148), and 
(2) non-endometriosis groups (n=150). P53 gene polymorphisms include codon11 Glu/Gln or Lys (GAG->CAG 
or AAG), codon 72 Arg/Pro (CGC->CCC), and codon 248 Arg/Thr (CGG->TCG). These gene polymorphisms 
were amplified by polymerase chain reaction and detected by electrophoresis after restriction enzyme (Taq I, 
BstU I, Hap II) digestions. Associations between the endometriosis and p53 polymorphisms were evaluated.  
Results: The distributions of p53 codon 72 polymorphisms in both groups were significantly different. The 
proportions of Arg homozygotes/heterozygotes/Pro homozygotes in both groups were 9.5/66.2/24.3% and 
30.7/50/19.3%. The proportions of Arg/Pro alleles were 42.6/57.4% and 56/44%. The distributions of p53 codon 
11 and 248 polymorphisms in both groups were non-significantly different. All individuals appeared the wild 
genotypes (Glu11 and Arg248 homozygotes).  
Conclusion: Association between endometriosis and p53 codon 72 polymorphism exists. P53 codon 72*Pro-
related genotype and allele are related with higher susceptibility of endometriosis. P53 codon 11 and 248 
polymorphisms are not related with endometriosis susceptibility.  
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1.  Introduction 
Endometriosis, a common 
polygenic/multifactorial disease, might be caused by 
an interaction between multiple genes as well as the 
environment [1]. Endometriosis displays features 
similar to malignancy, including local invasion and 
aggressive spread to distant organs. Its monoclonal 
origin indicates the neoplastic and genetic natures of 
most endometriotic lesions [2]. Genomic alterations 
may represent important events in the development of 
endometriosis. Tumor suppressor genes play a role in 
the regulation of cell growth and prevention of 
carcinogenesis. The altered tumor suppressor genes 
might be related with the development of 
endometriosis [3].  
p53, a representative tumor suppressor, is 
involved in cell proliferation and progression of 
various tumor types. There is discrepancy about this 
presentation of p53 polymorphisms and various 
tumors. The p53*Arg72 homozygote is considered to 
be a risk factor in the development of cancer [4]. In 
contrast, some investigators demonstrated the non-
association between the different p53 polymorphisms 
and individual cancer development [5]; other studies 
revealed the higher risks in the individuals with 
p53*Pro72 homozygote [6,7]. Furthermore, some 
investigators also demonstrated the associations of 
individual disorders with p53 codon 248 (Table 5).  
Scanty literature presented the association 
between the endometriosis and p53 polymorphism. 
High frequency of p53 locus deletion was observed in 
the endometriosis specimens [8]. The p53 protein 
abnormalities and chromosomal aberrations may be 
involved in malignant transformation of ovarian 
endometriosis [9]. In contrast, some investigators have 
demonstrated the undetectable expression of p53 in 
the endometriosis specimens [10-12]. To resolve these 
issues, we aimed to detect the p53 codon 11, 72, and 
248 polymorphisms in Taiwanese women with or 
without endometriosis. To the best of our knowledge, 
this report is the largest survey in this aspect. 
Furthermore, it is also the first report about the 
distributions of p53 codon 11 and 248 polymorphisms 
in endometriosis.  
2.  Material and methods 
Pre-menopausal Taiwanese women with 
surgically and histologically diagnosed endometriosis 
were included prospectively. All patients were 
divided into two groups: (1) moderate/severe 
endometriosis (n=119, according to revised American 
Fertility Society classification); and (2) non-
endometriosis group (n=108). The non-endometriosis 
statuses were confirmed during the cesarean section 
or diagnostic laparoscopy. All operations were 
performed by same surgeon (Hsieh YY). All women 
accepted the peripheral blood sampling for genotype Int. J. Biol. Sci. 2006, 2   
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analyses. There were non-significant differences 
between both groups in age, weight, and height. The 
experiment was approved by Ethical Committee and 
Institutional Review Board of the China Medical 
University Hospital. Informed consent was signed by 
all the women who donated their blood.  
The genomic DNA was prepared from peripheral 
blood leukocytes by use of a genomic DNA isolation 
kit (Blossom, Taipei, Taiwan). A total of 50 ng 
genomic DNA was mixed with 20 pmol of each 
polymerase chain reaction (PCR) primer in a total 
volume of 25 μl containing 10 mM Tris-HCL pH 8.3, 
50 mM potassium chloride, 2.0 mM magnesium 
chloride, 0.2 mM each deoxyribonucleotide 
triphosphate, and 1 U DNA polymerase (Amplitag; 
Perkin-Elmer, Foster City, CA, USA).  
The primer Pro72 was designed for p53 codon 72 
in proline (Pro) form and Arg72 for arginine (Arg) 
form, according to the procedure described by Storey 
et al. [4]. P53codon 11 and 248 gene polymorphisms 
were determined according as the modified conditions 
of previous reports [13]. The SNP information for the 
genes involved was obtained through internet 
(http://www.ncbi.nlm.nih.gov/LocusLink/). The 
PCR conditions and restriction digestion of each SNP 
were listed in Table 1. The PCR amplification was 
performed in a programmable thermal cycler 
GenAmp PCR system 2400 (Perkin Elmer Applied 
Biosystems, Foster City, CA, USA). After PCR 
amplification, the individual gene polymorphisms 
were analyzed by gel electrophoresis of the PCR 
products after restriction enzyme digestions (New 
England Biolabs, Inc, Beverly, MA). The primer 
sequences, PCR conditions and related base pairs for 
the wild and mutant types were listed in Table 1.  
Genotypes and allelic frequencies for p53 codon 
11, 72 and 248 gene polymorphisms in both groups 
were compared. Correlations of these gene 
polymorphisms and endometriosis were evaluated. 
Allelic frequencies are expressed as a percentage of 
the total number of alleles. The SAS package (Version 
8.1, SAS Institute Inc., Cary, North Carolina, USA) 
with  χ2  test  was utilized for statistical analyses. A p-
value of <.05 was considered statistically significant.  
3.  Results 
Genotype proportions of different p53 codon 11 
gene polymorphisms in both groups were non-
significantly different (Table 2). All individuals 
appeared the wild genotype (Glu11) and allele. 
Proportions of p53*Glu homozygote/heterozygote 
(Glu/Gln, Glu/Lys)/Gln or Lys homozygote in both 
groups were: (1) 100/0/0% and (2) 100/0/0%, 
respectively. The proportions of Glu/Gln/Lys alleles 
in both groups were all 100/0/0%. There was no 
mutated genotype (p53 codon 11*Glu/Glu, Glu/Lys, 
Glu/Gln, Lys/Lys) observed in all individuals.  
In contrast, the proportions of different p53 
codon 72 genotypes in both groups were significantly 
different. The proportions of Arg 
homozygote/heterozygote/Pro homozygote in 
endometriosis and non-endometriosis populations 
were 9.5/66.2/24.3% and 30.7/50/19.3%, respectively 
(p-value=0.0001, Table 3). The distributions of 
Arg/Pro alleles in both groups were 42.6/57.4% and 
56/44%, respectively (p-value=0.001, Table 3). There 
were increased numbers of Pro-related genotype (Pro 
homozygote and Arg/Pro heterozygote) and allele in 
endometriosis group compared to non-endometriosis 
group. It suggested the correlations between the Pro72 
and endometriosis.  
Genotype proportions of p53 codon 248 
polymorphisms in both groups were also non-
significantly different (Table 4). Proportions of p53 
codon 248*Arg homozygote/heterozygote (Arg/Trp, 
Arg/Gln)/Trp or Gln homozygotes in both groups 
were: (1) 100/0/0% and (2) 100/0/0%, respectively. 
The proportions of Arg/Trp/Gln alleles in both 
groups were all 100/0/0% (Table 4). All individuals in 
both groups appear the wild (Arg248) genotype and 
allele. There was no mutated genotype (Trp, Gln) for 
p53 codon 248 observed in all individuals.  
4.  Discussion 
Endometriosis is a common disorder in women, 
but its etiology remains unclear. The prevalence of 
endometriosis is 10% in the general population [14] 
and as high as 30-40% in infertile women [15]. Some 
heritable genetic defects might contribute to the 
development of endometriosis [16]. Somatic genetic 
alterations have been identified in endometriotic 
lesions, which might be related to its initiation and 
progression [17]. Kosugi et al. [18] demonstrated the 
increased heterogeneity and aneuploidy of 
chromosome 17 in endometriosis specimen. Because 
p53 is located in chromosome 17, the chromosome 17 
aneuploidy might impair the function of p53, which 
influences the further progression of endometriosis.  
The p53 gene and its encoded protein are related 
with the regulation of cell cycle, cellular growth, and 
apoptosis. It is a gatekeeper or guardian of the cell 
division [19]. The p53 mutations are associated with 
instability of cell development and cycle progression 
[20]. The wild-type p53 protein is a DNA-binding 
transcription factor that activates other tumor 
suppressor genes (e.g., p21, MDM2, GADD45, Bax), 
that are required for the regulation of cell cycle 
progression or apoptosis in response to DNA damage 
[21]. Alterations of p53 are related to the induction of 
apoptosis in malignant tumors.  
Individuals lacking functional p53 might be 
associated with tumor development. Abnormal p53 
presentation has been observed in some tumor 
specimens, including the cervical carcinoma [22], 
ovarian carcinoma [23], bladder cancer [24], prostate 
cancer [25], hepatoma [7], gastric cancer [26], lung 
cancer [7], brain tumor [27], esophageal carcinoma [28], 
breast cancer [29], lymphoma [30], etc. Mutated p53 
gene or malfunctioned p53 protein has often observed 
in patients with most types of malignancies [20].  
Single nucleotide polymorphisms (SNPs) provide 
a new way for the identification of complex gene-Int. J. Biol. Sci. 2006, 2   
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associated diseases such as endometriosis. Tumor 
suppressor-related SNPs might directly or indirectly 
affect tumor progression as well as the further 
interruption of cell cycles. Allelic polymorphisms that 
occur in the regulatory regions of these tumor 
suppressor genes are closely associated with 
malignant changes. Reviewing MEDLINE database, 
we observed the correlation of numerous p53 gene 
polymorphisms with individual diseases (Table 5). 
However, few investigators demonstrated their 
correlation with endometriosis.  
In fact, there are discrepancies about the 
distribution of p53 polymorphism in different 
malignancy. The p53 Arg72 homozygote is a 
significant risk factor in the development of invasive 
form of human papilloma virus-associated cancers [4]. 
In contrast, some investigators demonstrated the non-
association between the cervical cancer and different 
p53 polymorphisms [5]. Furthermore, some reports 
even revealed that Pro72 homozygote is a risk factor 
of lung and hepatocellular carcinoma [7]. In the study 
of lung carcinoma, Wang et al. [35] found those 
patients with p53 Arg72 or Pro72 homozygous had 
worse prognoses compared with those with the 
heterozygous form.  
Recently, Omori et al. [31] demonstrated that the 
non-association between the endometriosis and p53 
codon 72 polymorphism. In their study, the 
proportions of Arg homozygotes/heterozygotes/Pro 
homozygotes in endometriosis and control groups 
were 35.2/48.6%/16.2% and 39.4/41.7/18.9 %, 
respectively. We can see their controls’ distributions 
were compatible with ours. However, the percentage 
in endometriosis individuals is different from that of 
ours. This discrepancy may be due to the different 
endometriosis staging or racial variation. In this series, 
we observed that Arg72 homozygote is related with 
lower susceptibility of endometriosis development. 
The Pro forms of codon 72 in p53 (Pro homozygotes or 
heterozygotes) are related with the higher 
susceptibility of endometriosis development. Our 
finding was compatible with Wang et al. [7] and Yu et 
al. [6], who demonstrated the association between the 
Pro homozygotes and lung or hepatocellular 
carcinoma. Combined these above studies, it 
suggested the dominant p53* Pro forms is associated 
with the development of endometriosis in Taiwanese 
population.  
Most cancer-related mutations of p53 are 
clustered in the four so-called 'hot spots', codon 175, 
248, 273 and 281/282 [32]. Numerous reports 
presented the correlation statuses of p53 codon 248 
polymorphism and individual diseases (Table 5). In 
this study, we noted the mutated somatic mutation of 
p53 condon 11 and 248 could not be observed in the 
peripheral lymphocytes from endometriosis 
populations. Therefore, these two SNPs will not 
become useful candidates for the suspecting the 
susceptibility of endometriosis. Presumably, the 
distinct biological condition caused by p53 genotype 
will be among various genetic, dietary, and 
environmental factors regulating hormonal and non-
hormonal conditions in the development of 
endometriosis. These differences also reflect the 
etiological contributions of endogenous rather than 
exogenous factors to endometriosis. Furthermore, 
these polymorphisms might be in linkage 
disequilibrium with an unidentified functional 
polymorphism in p53 that influences endometriosis 
susceptibility.  
In conclusion, the association between 
endometriosis and p53 polymorphism exists. The p53 
Arg72 homozygotes are related with lower 
susceptibility of endometriosis development. The 
Pro72 homozygotes or heterozygotes are related with 
higher susceptibility of endometriosis development. 
The p53 codon 72 polymorphisms may become a 
useful marker to predict the endometriosis 
development. In contrast, the p53 codon 11 and 248 
are not candidates for the useful marker of the 
endometriosis screening. Although the real role of p53 
polymorphism has not been clarified, it deserves more 
attentions in the study of endometriosis and the 
development of gene therapy. However, the real roles 
of these p53 gene polymorphisms upon endometriosis 
remain to be clarified. Lager cohort recruitment is 
request for its further clarification. After the 
elucidation of these issues, some tumor suppressor 
gene polymorphisms might become useful markers to 
predict the future development of endometriosis as 
well as the development and intervention of genetic 
therapy.  
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Figures and Tables 
Table 1. The primer sequences and PCR conditions for p53 codon 11, 72 and 248 gene polymorphisms 
Polymorphisms 
(locations) 
Primers sequences (5’->3’)*  Denature 
(oC/sec) 
Annealing 
(oC/sec) 
Extention 
(oC/sec) 
Restriction 
enzyme (oC/min) 
SNP 
sequence 
Allele 
(a.a.) 
DNA 
fragment 
size (bp) 
p53 codon 11  F- 
CTTGGGTTGTGGTGAAACATTG; 
R- 
GTCAGTCCCATGAATTTTCGCT 
94/30  55/30 72/30  1 unit Taq I in 10 
μL buffer at 65oC 
for 30 min  
GAG (wild)  
CAG/AAG 
(mutant) 
Glu 
Gln/Lys 
239+140 
379 
p53 codon 72  F-TCCCCCTTGCCGTCCCAA;  
R-CGTGCAAGTCACAGACTT 
 
95/30  58/30 72/45  1 unit BstU I in 10 
μL buffer at 37oC 
for 30 min 
CGC (wild) 
CCC 
(mutant) 
Arg 
Pro 
279 
160+119 
p53 codon 248 
(exon 7) 
F- 
TAGGTTGGCTCTGACTGTACCA;  
R- 
TGTGATGAGAGGTGGATGGGTA 
 
94/30  58/30 72/30  1 unit Hap II in 10 
μL buffer at 65oC 
for 30 min 
CGG (wild) 
TGG/CAG 
(mutant) 
Arg 
Trp/Gln 
164+69 
233 
 
*F and R indicate forward and reverse primers 
Table 2. Genotype and allele frequency of p53 codon 11 polymorphisms in populations with and without endometriosis. 
  Endometriosis n=148 (%)  Non-endometriosis n=150 (%)  p-value 
Genotype       NS 
Glu/Glu  148 (100)  150 (100)   
Glu /Gln, Glu/Lys,   0  0   
Gln/Gln, Lys /Lys  0  0   
Allele frequency        
Glu  296 (100)  300 (100)  NS 
Gln 0  0   
Lys 0  0   
Table 3. Genotype and allele frequency of p53 codon 72 polymorphisms in populations with and without endometriosis.  
  Endometriosis n=148 (%)  Non-endometriosis n=150 (%)  p-value 
Genotype     0.0001 
Arg/Arg  14 (9.5)  47 (31.4)   
Arg /Pro  98 (66.2)  74 (49.3)   
Pro/Pro 36(24.3) 29  (19.3)   
Allele frequency      0.001 
Arg  126 (42.6)  168 (56)   
Pro  170 (57.4)  132 (44)   
NS: non-significantly different 
Table 4. Genotype and allele frequency of p53 codon 248 polymorphisms in populations with and without endometriosis. 
  Endometriosis, n=148 (%)  Non-endometriosis, n=150 (%)  p-value 
Genotype       NS 
Arg/Arg  148 (100)  150 (100)   
Arg/Trp, Arg/Gln  0  0   
Trp/Trp, Gln/Gln  0  0   
Allele frequency       NS 
Arg  296 (100)  300 (100)   
Trp 0  0   
Gln 0  0   
NS: non-significantly different Int. J. Biol. Sci. 2006, 2   
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Table 5. Correlations of p53 codon 11, 72, and 248 gene polymorphisms with individual diseases  
Correlation Non-correlation 
SNP Location  Diseases and references  SNP Location  Diseases and references 
Codon 11  Gastric cancer [33]  Codon 72  Gastric cancer [46] a 
Codon 72*Arg  Gastric cancer [34] a Codon  72  Cervical cancer [47,48] b 
Codon 72*Arg  Cutaneous melanoma [35] a Codon  72  Cervical cancer and human papillomavirus-related diseases [49] b 
Codon 72*Pro  Lung cancer [36] a Codon  72  Colorectal cancer [38] a 
Codon 72*Arg  Lung cancer [37] b Codon  72  Endometriosis [31] a 
Codon 72*Arg  Breast cancer [38] a Codon  72  Coronary artery disease [50] a 
codon 248  Adrenal neoplasm [39] b Codon  248  Pancreatic cancer [13] b 
codon 248  Squamous cell carcinoma in eyes [40] b    
codon 248  Lung cancer [41] b    
codon 248  Ovarian cancer [42] b    
codon 248  Gastric carcinoma [43] b    
codon 248  Ulcerative colitis [44] b    
codon 248  Acute lymphoblastic leukemia [45] a    
a: Gene extracted from peripheral blood; 
b: Gene extracted from tumor tissue specimen. 
Figure 1. Electrophoresis of p53 codon 11, 72, and 248. (A) p53 codon 11 (Marker 1. Glu homozygote; 2. Gln/Lys 
heterozygote) (*products of non-complete PCR reaction with primers). (B) p53 codon 72 (Marker 1. Arg/Pro heterozygosity; 
2. Arg homozygosity; 3. Pro homozygosity). (C) p53 codon 248 (marker 1. Trp/Gln heterozygosity; 2. Arg homozygosity) 
 